MannKind Corporation MNKD
4.19 USD -0.04 (-0.95%)
At closeNov 11, 2026, 6:06 PM EST
4.14 -0.05 -1.15%
After hours · Nov 11, 6:06 PM ET
4.15 Day range 4.23
2.23 52-week range 6.51
- YTD
- -26.10%
- 1 year
- -20.19%
News
seekingalpha.com MannKind's ReadyFlow Launch Keeps The Bull Case Alive MNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main…
benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $4.75 to $5.- benzinga.com Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10 Cantor Fitzgerald analyst Olivia Brayer Saunders maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
seekingalpha.com MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
defenseworld.net MannKind Q3 Earnings Call Highlights MannKind (NASDAQ: MNKD) expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
marketbeat.com MannKind Q3 Earnings Call Highlights MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
zacks.com Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
globenewswire.com MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after…
marketbeat.com MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF,…
benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
benzinga.com Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10 Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
globenewswire.com MannKind to Participate in the Chardan Healthcare Conference DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a…
benzinga.com Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across…
globenewswire.com MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across…- benzinga.com Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5 Truist Securities analyst Gregory Renza maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6 to $5.
marketbeat.com MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major…
benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
benzinga.com Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.- benzinga.com MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential…
globenewswire.com MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential…
globenewswire.com MannKind to Present at Upcoming Investor Conferences DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
zacks.com FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.- benzinga.com MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the selling stockholders (the "selling stockholders") identified in this prospectus supplement of up…
seekingalpha.com MannKind: New Approvals Majorly Increase MannKind's Prospects Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity…- benzinga.com Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
seekingalpha.com MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
marketbeat.com MannKind Q2 Earnings Call Highlights MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased…
zacks.com Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
benzinga.com MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 120 percent decrease over earnings of $0.05…- benzinga.com Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $11 to $14.
- benzinga.com MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in…
benzinga.com FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
benzinga.com MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24 MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…- benzinga.com MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chronic kidney disease address fluid overload earlier, before worsening symptoms may lead to emergency…
- benzinga.com MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE…
- benzinga.com Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize…
benzinga.com Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against Occidental Petroleum.- benzinga.com MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in…
- benzinga.com MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of Afrezza MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older…
- benzinga.com MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With Diabetes Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care…
benzinga.com MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8 MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung…- benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $3.5 to $4.75.
- benzinga.com Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10 Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
- benzinga.com Mizuho Maintains Outperform on MannKind, Lowers Price Target to $7 Mizuho analyst Anthony Petrone maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $8 to $7.
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
benzinga.com HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $10 HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and raises the price target from $8 to $10.